TC Biopharm (Holdings) (TCBP) Stock Analysis

What TC Biopharm (Holdings) does

Operating as a clinical-stage biopharmaceutical entity, TC Biopharm (Holdings) Plc is dedicated to pioneering immunotherapy solutions, leveraging its proprietary allogeneic gamma delta T cell platform. Its developmental portfolio includes OmnImmune, an unmodified cellular therapy aimed at acute myeloid leukemia, and ImmuniStim, another unmodified cellular therapy designed to combat COVID-19. The company was established in 2013 and is headquartered in Motherwell, United Kingdom.

Key metrics

ETFs linked to TCBP

Broad-market and Healthcare sector ETFs an investor holding TC Biopharm (Holdings) is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how TCBP fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for TC Biopharm (Holdings)?

TC Biopharm (Holdings) trades under the ticker TCBP on NASDAQ.

Which exchange is TCBP listed on?

TCBP is listed on NASDAQ.

What sector does TC Biopharm (Holdings) operate in?

TC Biopharm (Holdings) is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze TCBP in a portfolio?

PortView shows TCBP's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.